Nature’s Toolbox (NTx), a life science company, secured $15 million in venture debt from J.P. Morgan. The financing is designed to fuel the deployment of NTx systems across major pharmaceutical, governmental and clinical organizations.
“As we prepare for the commercial expansion of our distributed biomanufacturing technology, this financing will help us broaden our reach and fulfill our mission to revolutionize biomaterials production by making it more accessible, scalable and cost-effective,” Jamie Coffin, CEO of NTx, said. “We are excited to have the support of J.P. Morgan and look forward to leveraging their expertise in working with growth-stage life sciences companies.”
“J.P. Morgan is proud to work with NTx as they continue to scale,” Liz Crum, co-head of West Life Sciences within J.P. Morgan’s innovation economy business, said. “It’s an exciting time to be working with life sciences companies, and we look forward to supporting the role NTx plays in transforming the way biomaterials are produced and expediting the delivery of personalized therapies.”
